Cefazolin versus vancomycin for neurosurgical operative prophylaxis – A single institution retrospective cohort study
Introduction
Healthcare-associated infections can be costly to hospitals and dangerous to patients, especially when related to surgery [1]. Surgical site infections (SSI) for patients undergoing neurosurgery are the costliest among the surgical specialties, as each SSI was estimated to cost $23,755 in 2010 [2]. SSI incidence rates in neurosurgery vary by procedure and location but are estimated occur at a rate of 1–10% [[3], [4], [5], [6], [7], [8]]. Approximately 14 million neurosurgical procedures were performed in 2017, which would equate to anywhere from 140,000 to 1.4 million neurosurgical patients developing potentially dangerous SSIs [9,10].
A number of different variables have been identified as risk factors for development of SSI in neurosurgical procedures such as surgical duration, wound contamination, and CSF leak [4,5,11]. Although past studies of neurosurgical pre-incisional antibiotic prophylaxis have demonstrated mixed efficacy, general expert consensus, including The United States Center for Disease Control and Prevention (CDC) guidelines for global reduction of SSIs, supports antibiotic prophylaxis [4,[12], [13], [14], [15], [16]].
Recommended prophylactic agents for neurosurgical procedures are cefazolin, gentamicin, and vancomycin [17]. Cefazolin is considered to be a reasonable first-line option that covers skin commensals and other organisms frequently implicated in neurosurgical SSI [18]. One Italian study of cerebrospinal fluid (CSF) shunt insertions determined that vancomycin prophylaxis reduced shunt infection rate and mortality compared to cefazolin [19]. Another study from that hospital had previously reported that the majority of infections in neurosurgical patients were caused by Staphylococcus aureus, with 39% of those being methicillin-resistant [20]. In this study, we aimed to determine if patients who underwent vancomycin prophylaxis instead of cefazolin prophylaxis experienced a significantly different incidence of SSIs following general neurosurgical procedures.
Section snippets
Patients and methods
In this retrospective cohort study, we reviewed the records of patients who underwent a neurosurgical operation between January of 2013 and April of 2016 in one particular hospital. In mid-April 2016, surgeries were relocated to a newer hospital. Patients were included if they were not incarcerated and underwent a procedure by one of the three attending neurosurgeons who were continuously employed during the study period. We excluded cases in which the prophylactic antibiotic administered was
Results
A total of 859 operations met the study criteria; 664 patients received cefazolin, and 195 received vancomycin. Patient demographic data and other descriptive statistics can be found in Table 1. Using the standard SSI definition, there were 23 (3.4%) SSIs, with 18 (2.7%) in the cefazolin group and 5 (2.6%) in the vancomycin group. Of these SSIs, 22 had a confirmed culture or histological diagnosis, and 4 were clinically diagnosed. Using the study SSI definition, there were 22 (2.6%), with 14
Discussion
Using both the standard SSI definition and our modified definition, which expands the analysis to one year after the operation and requires a histologically-confirmed or culture-confirmed diagnosis, our results demonstrated no difference in incidence of SSIs between patients who received solely cefazolin compared to vancomycin for neurosurgical prophylaxis. The incidence rate of SSIs (2.6–3.4%) at our institution was consistent with previously reported statistics [[3], [4], [5], [6], [7], [8]].
Conclusion
Choice of cefazolin versus vancomycin prophylaxis was not significantly associated with a difference in rates of SSI development. Previous incision at or near the surgical site within the previous year was associated with increased risk of developing a wound infection. Although our study did not demonstrate statistical significance, patients who receive cefazolin prophylaxis may be more likely to have S. aureus isolated from wound cultures. Institutions should carefully review antibiogram
Conflicts of interest
The authors report that there are no conflicts of interest or financial relationships to report.
Acknowledgements
None.
References (38)
- et al.
Risk factors of neurosurgical site infection after craniotomy: a systematic review and meta-analysis
Am. J. Infect. Control
(2017) - et al.
The role of antibiotic prophylaxis in clean neurosurgery
World Neurosurg.
(2017) - et al.
Vancomycin versus cefazolin prophylaxis for cerebrospinal shunt placement in a hospital with a high prevalence of meticillin-resistant Staphylococcus aureus
J. Hosp. Infect.
(2008) - et al.
Penicillin allergy and surgical prophylaxis: cephalosporin cross-reactivity risk in a pediatric tertiary care center
J. Pediatr. Surg.
(2015) - et al.
Cross-reactivity and tolerability of cephalosporins in patients with IgE-Mediated hypersensitivity to penicillins
J. Allergy Clin. Immunol. Pract.
(2018) - et al.
Financial impact of surgical site infections on hospitals: the hospital management perspective
JAMA Surg.
(2013) - et al.
Costs associated with surgical site infections in veterans affairs hospitals
JAMA Surg.
(2014) - et al.
Surgical site infections in standard neurosurgery procedures- a study of incidence, impact and potential risk factors
Br. J. Neurosurg.
(2014) - et al.
Risk factors for neurosurgical site infections after craniotomy: a critical reappraisal of antibiotic prophylaxis on 4,578 patients
Br. J. Neurosurg.
(2005) - et al.
Operative duration and risk of surgical site infection in neurosurgery
World Neurosurg.
(2016)
Prospective multicenter surveillance study of surgical site infection after intracranial procedures in Korea : a preliminary study
J. Korean Neurosurg. Soc.
Epidemiology of surgical site infection in a neurosurgery department
Br. J. Neurosurg.
Global neurosurgery: the current capacity and deficit in the provision of essential neurosurgical care. Executive Summary of the Global Neurosurgery Initiative at the Program in Global Surgery and Social Change
J. Neurosurg.
Operative and consultative proportions of neurosurgical disease worldwide: estimation from the surgeon perspective
J. Neurosurg.
Neurosurgical site infection prevention: single institute experience
Turk. Neurosurg.
Centers for disease control and prevention guideline for the prevention of surgical site infection
JAMA Surg.
Risk factors for neurosurgical site infections: an 18-month prospective survey
J. Neurosurg.
The French Study Group of Neurosurgical I, Sehp, Paris-Nord CC. Risk Factors for Neurosurgical Site Infections after Craniotomy: A Prospective Multicenter Study of 2944 Patients
Neurosurgery
2nd. Efficacy of prophylactic antibiotic therapy in spinal surgery: a meta-analysis
Neurosurgery
Cited by (5)
Evaluating the role of methicillin-resistant Staphylococcus aureus (MRSA)-specific antibiotic prophylaxis for neurosurgical patients
2021, Clinical Neurology and NeurosurgeryCitation Excerpt :Given the continued rise of MRSA colonization [9] and lack of consensus on the appropriate antibiotic prophylaxis for surgery in this population, we aimed to evaluate whether the use of MRSA-specific antibiotics in those with MRSA colonization decreased SSI incidence. We report an overall SSI rate of 3.9 % in the neurosurgical population, which compares favorably to prior retrospective [19,20] and prospective studies [21–24]. Previous studies have reported an SSI incidence of 0.5%–18.8% in spinal surgeries [25–28] compared with 1%–8% in craniotomies [1,20,21,29,30].
Impact of penicillin allergy labels on surgical site infections in a large UK cohort of gastrointestinal surgery patients
2024, JAC-Antimicrobial ResistanceDoes a Reported Penicillin Allergy Affect Outcomes Following Elective Posterior Lumbar Fusions?
2022, International Journal of Spine Surgery